Every Form 4 that Tenon Medical, Inc. Warrant (TNONW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNONW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNONW filings page.
Tenon Medical, Inc. (TNON) reported that HRT FINANCIAL LP, a ten percent owner, executed multiple open-market transactions in its common stock from September 8–10, 2026. The firm purchased 108,140 shares and sold 125,925 shares, for a net of 17,785 more shares sold than bought.
Reported prices ranged from $2.61 to $5.56 per share, including purchases such as 31,227 shares at $2.92 and sales such as 65,582 shares at $5.56. A footnote states that the transactions with the related note resulted in short sales. No Rule 10b5-1 trading plan is reported.
Tenon Medical, Inc. (TNON) reported that its Chief Financial Officer, Kevin Williamson, had 30 restricted stock units vest and convert into 30 shares of common stock on September 8, 2026, from RSUs granted November 5, 2024 and adjusted for a 1-for-35 reverse stock split effected August 10, 2026. On September 9, 2026, 11 of the resulting common shares were delivered or withheld at a price of $3.45 per share to pay the associated tax liability.
Tenon Medical, Inc. (TNON) reported that major shareholder HRT FINANCIAL LP, a ten percent owner, both bought and sold Tenon common stock in early September 2026. On September 3, HRT FINANCIAL LP purchased 1,658 shares at $3.98 per share, then on September 4 sold 1,506 shares at $3.70 per share in open market or private transactions. Overall, these reported trades represent a small net purchase of 152 shares, and no post-transaction share balance is stated.
Tenon Medical, Inc. (TNON) had insider activity reported by large shareholder HRT Financial LP. On September 1, 2026, HRT purchased 1,790 shares of common stock at $4.57 per share, and on September 2, 2026, it sold 450 shares at $4.53 per share, resulting in a net purchase of 1,340 shares. No Rule 10b5-1 trading plan is reported.
Tenon Medical, Inc. (TNON) reported insider trading activity by ten percent owner HRT FINANCIAL LP in its common stock. On August 28, 2026, HRT purchased 12,376 shares at $5.21 and 5,981 shares at $6.35, and sold 4,932 shares at $7.07 and 2,091 shares at $7.90. On August 31, 2026, it sold an additional 1,276 shares at $4.66. Prices are per-share open-market or private transaction figures, and the filing does not state HRT’s post-transaction holdings.
Tenon Medical, Inc. (TNON) had a Form 4 filed by reporting person HRT FINANCIAL LP, identified as a ten percent owner. On 2026-08-27, HRT FINANCIAL LP reported a sale of 419 shares of common stock at $4.96 per share, leaving 9,604 shares held directly. A footnote states that the transaction resulted in short sales, and that full price details by execution are available upon request to specified parties.
Tenon Medical, Inc. director Robert K. Weigle converted 10,732 Restricted Stock Units, granted on October 13, 2025, into 10,732 shares of common stock on July 31, 2026 at $0.00 per share. After this RSU conversion, he directly held 18,284 shares of Tenon Medical common stock.
Tenon Medical director Kristine M Jacques converted 10,147 restricted stock units, granted on October 13, 2025, into 10,147 shares of common stock on July 31, 2026. Following this RSU conversion, she directly holds 20,876 shares of Tenon Medical common stock.
Tenon Medical, Inc. director Ivan Howard exercised 10,732 restricted stock units on July 31, 2026, converting them into 10,732 shares of common stock at $0.00 per share. The RSUs were fully converted, and his direct ownership increased to 19,194 common shares after the transaction.
Tenon Medical, Inc. director Stephen Hochschuler converted 10,732 restricted stock units granted on October 13, 2025 into 10,732 shares of common stock on July 31, 2026 at a stated price of $0.00 per share. After the conversion, he directly holds 18,670 shares of Tenon Medical common stock and no remaining units from this grant.
Tenon Medical director Richard Ferrari converted 64,479 restricted stock units into 64,479 shares of common stock on July 31, 2026. Each unit represented a contingent right to receive one share. After this settlement, he directly owned 135,243 shares of Tenon Medical common stock.
Tenon Medical, Inc. Chief Financial Officer Kevin Williamson reported equity compensation activity and related tax withholding. On July 31, 2026, 58,987 restricted stock units vested and converted into 58,987 shares of common stock. On August 3, 2026, 12,978 common shares were delivered/withheld at $0.198 per share to satisfy tax liabilities arising from this RSU vesting.
Tenon Medical director and Chief Technology Officer Richard Ginn reported the vesting and conversion of 126,577 restricted stock units into the same number of common shares on July 31, 2026, from RSUs granted on October 13, 2025. On August 3, 2026, he sold 44,809 common shares at $0.198 per share to pay tax liability related to this RSU vesting.
Tenon Medical, Inc. reported equity compensation activity by CEO and President Steven M. Foster140,936 Restricted Stock Units (RSUs) that were granted on October 13, 2025 converted into 140,936 shares of common stock, with each RSU representing a contingent right to one share.
In a related transaction on August 3, 2026, 41,788 shares of common stock were disposed of at $0.198 per share. Footnote disclosure states these shares were sold to pay the tax liability associated with the vesting of the RSUs, indicating a tax-withholding disposition rather than an open-market portfolio trade.
Geist Wyatt D. reported acquisition or exercise transactions in this Form 4 filing.
Tenon Medical, Inc. disclosed that on May 1, 2026 it issued 276,228 shares of common stock to SiVantage, Inc. under an Asset Purchase Agreement tied to a milestone achievement. Chief Innovation Officer Wyatt D. Geist has a 49.38% equity interest in SiVantage, giving him an indirect pecuniary interest in 136,401 of these shares, increasing his indirect holdings to 487,166 shares held by SiVantage. He also holds 157,569 shares directly and disclaims beneficial ownership of SiVantage’s shares except to the extent of his pecuniary interest.
Tenon Medical, Inc. reported an equity milestone payment tied to its acquisition of assets from SiVantage, Inc. Under an Asset Purchase Agreement dated August 1, 2025, the company issued 276,228 shares of common stock to SiVantage on May 1, 2026 after a specified milestone was achieved.
The Form 4 for Chief Commercial Officer Nathaniel A. Grawey reflects his indirect pecuniary interest in these shares through his 24.69% equity interest in SiVantage, corresponding to 68,201 shares. After this award, he holds 243,584 shares indirectly via SiVantage and 239,281 shares directly of Tenon Medical common stock.